RMD Maintained by Keybanc -- Price Target Raised to $267

gurufocus.com · 2026-08-31

On October 05, 2023, ResMed (RMD) has been maintained with an Overweight rating by Keybanc's analyst Brett Fishbin. The price target has been raised from $255.0

Read the full story at gurufocus.com →